Development asset linked to Shanghai Institute of in public FDA and regional records.
pharma · Decompensated Cirrhosis · Primary Ovarian Insufficiency
Shanghai Institute of
Chinese Academy of Sciences
Shanghai Institute of drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
114 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Employees
- 114
- Programs
- 2
- Drugs
- 4
- Patents
- 0
Shanghai Institute of pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Shanghai Institute of drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Shanghai Institute of in public FDA and regional records.
-
Development asset linked to Shanghai Institute of in public FDA and regional records.
-
Development asset linked to Shanghai Institute of in public FDA and regional records.